Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 731 clinical trials
PCOS Treatment Using DLBS3233, Metformin, and Combination of Both (POSITIF)  

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 26 Oct, 2022
  • 4 locations
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments

Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx. The International Agency for Cancer Research of World Health Organization (WHO) classified a dozen of HPV related high-risk cancer types, and recognized cervical …

vaginal biopsy
cone biopsy
dysplasia
human papillomavirus
lymphadenectomy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma is palliative and usually platinum based, and the patients often present with poor physical condition. Consequently, many of them are not able to withstand a platinum-based chemotherapy. The addition of taxanes to the armamentarium of drugs improve the outcome …

central nervous system disease
hepatitis c antibody
kidney function tests
oropharyngeal
tumor of the oropharynx
  • 0 views
  • 16 Feb, 2024
  • 20 locations
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

cancer therapy
biological therapy
measurable disease
electrocardiogram
serum bilirubin
  • 0 views
  • 16 Feb, 2024
  • 1 location
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL. The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in …

anaplastic large cell lymphoma
peripheral t-cell lymphoma
lenalidomide
  • 0 views
  • 16 Feb, 2024
  • 1 location
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing …

endometrioid adenocarcinoma of the endometrium
hepatitis
antiviral therapy
non-small cell lung cancer
hepatitis b surface antigen
  • 0 views
  • 16 Feb, 2024
  • 9 locations
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum …

metastatic head and neck squamous cell carcinoma
programmed cell death protein 1
carcinoma
measurable disease
capecitabine
  • 0 views
  • 16 Feb, 2024
  • 3 locations
A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.

carcinoma
measurable disease
brain metastases
head and neck carcinoma
neck cancer
  • 0 views
  • 05 Aug, 2020
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

microsatellite instability high
breast cancer
non-small cell lung cancer
zanubrutinib
diffuse large b-cell lymphoma
  • 0 views
  • 16 Feb, 2024
  • 4 locations
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year progression-free survival (PFS) and 2-year overall survival (OS) were the secondary endpoint. To evaluate the efficacy and …

  • 0 views
  • 21 Sep, 2021
  • 1 location